一、审议通过《关于选举公司董事长的议案》 公司董事会同意选举吴长虹女士为公司第六届董事会董事长，任期 自董事会审议通过之日起至第六届董事会任期届满之日止。 表决结果：同意 8 票，反对 0 票，弃权 0 票。 二、审议通过《关于变更公司法定代表人的议案》 证券代码：300452 证券简称：山河药辅 公告编号：2025-062 债券代码：123199 债券简称：山河转债 安徽山河药用辅料股份有限公司 第六届董事会第九次会议决议公告 本公司及董事会全体成员保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏。 安徽山河药用辅料股份有限公司（以下简称"公司"）第六届董事会 第九次会议于 2025 年 11 月 7 日上午在公司三楼会议室召开，应出席会议 董事8 人，实际出席会议董事 8 人。公司第六届董事会第九次会议通知已 于2025年11月6日以电子邮件、传真及电话通知的方式向全体董事送达， 会议由代理董事长宋道才先生主持。会议的召开符合《中华人民共和国公 司法》和《公司章程》的有关规定。本次会议经审议逐项表决作出如下决 议： 1、第六届董事会第九次会议决议 2、深交所要求的其他文件 特此公告。 安徽山河药 ...

天禾律师事务所 法律意见书 安徽天禾律师事务所 关于安徽山河药用辅料股份有限公司 2025年第二次临时股东会的法律意见书 天律意2025第02896号 致：安徽山河药用辅料股份有限公司 根据《中华人民共和国公司法》（下称"《公司法》"）、《中华人民共和国 证券法》（下称"《证券法》"）、中国证券监督管理委员会《上市公司股东会规 则》（下称"《股东会规则》"）以及《安徽山河药用辅料股份有限公司章程》（下 称"《公司章程》"）的有关规定，安徽天禾律师事务所接受安徽山河药用辅料股 份有限公司（下称"公司"）的委托，指派杨帆、王林律师（下称"天禾律师"）出 席公司 2025 年第二次临时股东会（下称"本次股东会"），并对本次股东会相关 事项进行见证，出具法律意见。 本法律意见书是天禾律师根据对本次股东会事实的了解及对我国现行法律、 法规和规范性文件的理解而出具的。 天禾律师同意将本法律意见书作为本次股东会的法定必备文件予以公告，并 依法对所出具的法律意见书承担责任。 天禾律师根据《证券法》相关规定的要求，按照律师行业公认的业务标准、 道德规范和勤勉尽责精神，对本次股东会的召集、召开、与会人员资格、表决程 序及其他相关 ...

证券代码：300452 证券简称：山河药辅 公告编号：2025-060 债券代码:123199 债券简称:山河转债 安徽山河药用辅料股份有限公司 2025 年第二次临时股东会决议公告 本公司及董事会全体成员保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完 整性承担个别及连带责任。 一、重要提示 2．网络投票时间：通过深圳证券交易所交易系统进行网络投票 的具体时间为：2025年11月6日上午9:15—9：25，9：30—11:30 和 下午13:00—15:00； 通过互联网投票系统投票的具体时间为：2025 年11月6日上午 9:15至2025年11月6日下午 15:00期间的任意时间。 3．股权登记日：2025年10月31日。 1、本次会议召开期间没有增加、否决或变更提案； 2、本次股东会以现场投票结合网络投票方式进行。 二、会议召开和出席情况 1．现场会议召开时间：2025年11月6日（星期四）下午15:00 本次股东会以现场与网络投票相结合的方式形成如下决议： 1、审议通过《关于补选公司第六届董事会非独立董事的议案》。 该议案的表决结果为：同意 70,081,0 ...

本公司及董事会全体成员保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完 整性承担个别及连带责任。 安徽山河药用辅料股份有限公司（下称"公司"）于 2025 年 11 月 6 日召开 2025 年第二次临时股东大会，审议通过了《关于补选公 司第六届董事会非独立董事的议案》，同意选举吴长虹女士为公司第 六届董事会非独立董事，任期自股东大会审议通过之日起至第六届董 事会届满之日止。 公司第六届董事会成员：吴长虹、宋道才、雷韩芳、刘路、独立 董事王宏、独立董事林平以及独立董事周建平、职工董事王传珍。 特此公告。 安徽山河药用辅料股份有限公司 董 事 会 证券代码：300452 证券简称：山河药辅 公告编号：2025-055 债券代码：123199 债券简称：山河转债 安徽山河药用辅料股份有限公司 关于完成补选第六届董事会非独立董事的公告 二〇二五年十月二十日 ...

Group 1 - Taifu Pump Industry has terminated the acquisition of 51% equity in Nanyang Huacheng [1] - Shareholder Fosun Pharma of Shanhe Pharmaceutical Auxiliary plans to reduce its stake by no more than 3% [1] - Several convertible bonds including Anji Convertible Bond, Longda Convertible Bond, and Oujing Convertible Bond will not undergo forced redemption [1][2] Group 2 - The following convertible bonds will not be adjusted: Oujing Convertible Bond, Longda Convertible Bond, and Tong 22 Convertible Bond [2] - New shares from Danna Biotechnology will be listed on the Beijing Stock Exchange [1] - North Mining Testing is also set to issue new shares on the Beijing Stock Exchange [1]

Summary of Key Points Core Viewpoint - Several companies are experiencing significant shareholder reductions, with some facing regulatory scrutiny for financial discrepancies [1] Group 1: Shareholder Reductions - Aohua Endoscopy's general manager Gu Xiaozhou plans to reduce holdings by no more than 2.6 million shares [1] - Tuosida's senior executive Huang Daibo intends to reduce holdings by no more than 0.9524% of shares [1] - Anke Intelligent Electric's actual controller Chen Xiaohui plans to reduce holdings by no more than 1% [1] - Shanhe Pharmaceutical's shareholder Fosun Pharma intends to reduce holdings by no more than 3% [1] - Digital Certification's shareholder Capital Information Development plans to reduce holdings by no more than 2% [1] - Saiwu Technology's shareholder Dongyun Chuangtou plans to reduce holdings by no more than 1% [1] - Kanglongda's shareholder Juyin Fund plans to reduce holdings by no more than 3% [1] - Zaiseng Technology's controlling shareholder Guo Mao has cumulatively reduced 9.45 million shares [1] - Weishi Electronics' controlling shareholder Watanabe Yōichi has reduced 0.89% of company shares [1] - Olin Bio's shareholder Shanghai Wushan has cumulatively reduced 3% of company shares [1] Group 2: Other Notable Events - Taifeng Pump Industry has terminated plans for a major asset restructuring [1] - Qingyue Technology is under investigation by the Securities Regulatory Commission for suspected false financial reporting [1] - Baismei's actual controller has received a notice of investigation from the Securities Regulatory Commission [1] - Taiyuan Car Factory will implement other risk warnings starting November 4 [1] - First Capital's subsidiary Yichuang Investment Bank has received a notice of investigation from the Securities Regulatory Commission [1]

Core Viewpoint - On October 31, six A-share listed companies disclosed their share reduction plans, with no companies announcing share increases on the same day [1]. Summary by Category Share Reduction Plans - Anke Zhidian: Shareholder Chen Xiaohui plans to reduce holdings by no more than 1% of the company's shares [2] - Shanhe Yaofu: Shareholder Fosun Pharma intends to reduce holdings by no more than 3.00% of shares [2] - Tuosida: Director and executive Huang Daibo plans to reduce holdings by no more than 0.95% of shares [2] - Saiwu Technology: Shareholder Dongyun Chuangtou plans to reduce holdings by no more than 1% of shares [2] - Dadi Xiong: Some directors and executives plan to collectively reduce holdings by no more than 0.75% of the company's shares [2] - Kanglongda: Shareholder Juyin Fund intends to reduce holdings by no more than 3.00% of shares [2]

Core Viewpoint - On October 31, six A-share listed companies disclosed their share reduction plans, with no companies announcing share increases on the same day [1]. Summary by Category Share Reduction Plans - Anke Intelligent Electric: Shareholder Chen Xiaohui plans to reduce holdings by no more than 1% of the company's shares [2]. - Shanhe Pharmaceutical: Shareholder Fosun Pharma intends to reduce holdings by no more than 3.00% of shares [2]. - Tuosida: Director and executive Huang Daibo plans to reduce holdings by no more than 0.95% of shares [2]. - Saiwu Technology: Shareholder Dongyun Venture Capital plans to reduce holdings by no more than 1% of shares [2]. - Dadi Bear: Some directors and executives plan to collectively reduce holdings by no more than 0.75% of shares [2]. - Kanglongda: Shareholder Juyin Fund plans to reduce holdings by no more than 3.00% of shares [2].

Core Viewpoint - Shanghai Fosun Pharmaceutical Industry Development Co., Ltd. plans to reduce its stake in Shanhe Pharmaceutical (300452) by up to 6.9787 million shares, representing no more than 3% of the company's total share capital within 90 days after a 15 trading day period from the announcement date [1] Group 1 - Fosun Pharmaceutical currently holds 21.6453 million shares in Shanhe Pharmaceutical, accounting for 9.23% of the company's total share capital [1]

Group 1 - Shanghai Fosun Pharmaceutical Industry Development Co., Ltd. plans to reduce its stake in Shanhe Pharmaceutical Excipients Co., Ltd. by up to approximately 6.98 million shares, which is no more than 3% of the total share capital after deducting repurchased shares [1] - The reduction will occur within 90 days after a 15 trading day period following the announcement [1] - Shanhe Pharmaceutical Excipients' revenue composition for the year 2024 is expected to be 100% from the pharmaceutical manufacturing industry [1] Group 2 - As of the report, Shanhe Pharmaceutical Excipients has a market capitalization of 3.3 billion yuan [2]